Quest Diagnostics Inc (DGX) was Downgraded by Mizuho to ” Neutral” and the brokerage firm has set the Price Target at $86. Earlier the firm had a rating of “Buy ” on the company shares. Mizuho advised their investors in a research report released on Aug 31, 2016.
On the company’s financial health, Quest Diagnostics Inc reported $1.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $1.32. The company had revenue of $1906.00 million for the quarter, compared to analysts expectations of $1905.57 million. The company’s revenue was down -1.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.25 EPS.
Quest Diagnostics Inc opened for trading at $83 and hit $84.56 on the upside on Monday, eventually ending the session at $84.33, with a gain of 1.63% or 1.35 points. The heightened volatility saw the trading volume jump to 11,97,025 shares. Company has a market cap of $11,723 M.
Investors should note that on Aug 17, 2016, Quest Diagnostics Inc announced a cash dividend of $0.4000. The company’s management has announced Sep 30, 2016 as the ex-dividend date and fixed the record date on Oct 4, 2016. The payable date has been fixed on Oct 19, 2016.
In a different news, on Aug 22, 2016, Jenne K Britell (director) sold 4,000 shares at $84.76 per share price. According to the SEC, on Aug 4, 2016, Jeffrey M Leiden (director) sold 6,345 shares at $85.63 per share price. On Jul 27, 2016, John B Ziegler (director) sold 1,000 shares at $84.36 per share price, according to the Form-4 filing with the securities and exchange commission.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.